Core Viewpoint - Incannex Healthcare Inc. is making significant progress in its IHL-42X development program for treating obstructive sleep apnea (OSA), with key milestones expected in the near future [2]. Operational Highlights - The company secured $12.5 million in private placement funding to support the ongoing IHL-42X Phase 2/3 clinical program [7]. - An OSA Clinical Advisory Board was formed, with Dr. Alison Wimms appointed to enhance collaboration and clinical development efforts [7]. - More than 120 patients have been dosed across 11 clinical trial sites in the Phase 2 portion of the RePOSA study [7]. Clinical Highlights - IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide, currently in the RePOSA Phase 2/3 clinical trial, which aims to enroll over 560 patients globally [6]. - The trial is evaluating two doses of IHL-42X compared to placebo over a four-week treatment period, with topline data expected in July 2025 [7][8]. - Positive topline results from a pharmacokinetics and safety study confirmed the bioavailability of both active components in IHL-42X [7]. Financial Results - General and Administrative (G&A) expenses for the three months ended March 31, 2025, were $2.27 million, down from $4.14 million in the same period of 2024 [7]. - Research and Development (R&D) expenses for the same period totaled $2.74 million, compared to $3.28 million in 2024 [7]. - The net loss for the three-month period ended March 31, 2025, was $3.97 million, a decrease from $6.03 million in the prior year [7].

– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing med ...